New principles in the treatment of hormonal refractory prostate cancer.
Nisen
Perry
P
Abbott Laboratories, Chicago, Illinois, USA.
D020533:Angiogenesis Inhibitors / Q000627:therapeutic use; D000970:Antineoplastic Agents / Q000627:therapeutic use; D000077868:Atrasentan; D002986:Clinical Trials as Topic; D065128:Endothelin Receptor Antagonists; D019332:Endothelin-1 / Q000037:antagonists & inhibitors / Q000097:blood; D006801:Humans; D008297:Male; D011471:Prostatic Neoplasms / Q000188:drug therapy / Q000628:therapy*; D011759:Pyrrolidines
D020533:Angiogenesis Inhibitors; D000970:Antineoplastic Agents; D065128:Endothelin Receptor Antagonists; D019332:Endothelin-1; D011759:Pyrrolidines; D000077868:Atrasentan